Literature DB >> 28302484

TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495.

Minting Ye1, Ting Wei2, Qiongyao Wang3, Yanqin Sun4, Ruixiang Tang5, Linlang Guo6, Weiliang Zhu7.   

Abstract

Studies have shown that TSPAN12 serves as an oncogenic gene or tumor suppressor depending on the types of cancer. However, its role in the drug resistance of small cell lung cancer (SCLC) is still unknown. In this study, we investigated whether TSPAN12 regulates chemoresistance, proliferation and tumor growth of SCLC under the regulation of miR-495 using two drug resistant cell lines. The results showed that down-regulation of TSPAN12 inhibited cells chemoresistance, proliferation and tumor growth. Besides, TSPAN12 elevation in SCLC specimens correlated with poor pathologic stage and shorter survival time. In addition, the dual luciferase assay indicated that TSPAN12 was one of the directly targeted genes of miR-495. Our study revealed that TSPAN12 promoted chemoresistance of SCLC under the regulation of miR-495. TSPAN12 depletion is a promising strategy for inhibiting the chemoresistance in SCLC.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Chemoresistance; SCLC; TSPAN12; miR-495

Mesh:

Substances:

Year:  2017        PMID: 28302484     DOI: 10.1016/j.bbrc.2017.03.044

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models.

Authors:  Yan Ting Shue; Jing Shan Lim; Julien Sage
Journal:  Transl Lung Cancer Res       Date:  2018-02

2.  miR-196b-5p-mediated downregulation of TSPAN12 and GATA6 promotes tumor progression in non-small cell lung cancer.

Authors:  Guang Liang; Wei Meng; Xiangjie Huang; Wangyu Zhu; Changtian Yin; Canwei Wang; Matteo Fassan; Yun Yu; Masahisa Kudo; Sisi Xiao; Chengguang Zhao; Peng Zou; Yumin Wang; Xiaokun Li; Carlo M Croce; Ri Cui
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-10       Impact factor: 11.205

Review 3.  MicroRNAs Involved in Small-cell Lung Cancer as Possible Agents for Treatment and Identification of New Targets.

Authors:  Ulrich H Weidle; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2021 Sep-Oct       Impact factor: 4.069

4.  miR-495 inhibits proliferation, migration, and invasion and induces apoptosis via inhibiting PBX3 in melanoma cells.

Authors:  Guangxiong Chen; Yijie Xie
Journal:  Onco Targets Ther       Date:  2018-04-05       Impact factor: 4.147

5.  miR-216a-5p inhibits malignant progression in small cell lung cancer: involvement of the Bcl-2 family proteins.

Authors:  Yanqin Sun; Bingshuang Hu; Yanhong Wang; Zhen Li; Jingfang Wu; Yunchu Yang; Yue Wei; Xiaofeng Peng; Hongling Chen; Rongqi Chen; Pingyan Jiang; Sixian Fang; Zhiwu Yu; Linlang Guo
Journal:  Cancer Manag Res       Date:  2018-10-18       Impact factor: 3.989

6.  Ring finger protein 152-dependent degradation of TSPAN12 suppresses hepatocellular carcinoma progression.

Authors:  Jian Wan; Shunfang Liu; Wanju Sun; Haiyi Yu; Wenlian Tang; Wei Liu; Jing Ji; Bin Liu
Journal:  Cancer Cell Int       Date:  2021-02-18       Impact factor: 5.722

7.  MEG3 LncRNA from Exosomes Released from Cancer-Associated Fibroblasts Enhances Cisplatin Chemoresistance in SCLC via a MiR-15a-5p/CCNE1 Axis.

Authors:  Yulu Sun; Guijun Hao; Mengqi Zhuang; Huijuan Lv; Chunhong Liu; Keli Su
Journal:  Yonsei Med J       Date:  2022-03       Impact factor: 2.759

8.  NSE, positively regulated by LINC00657-miR-93-5p axis, promotes small cell lung cancer (SCLC) invasion and epithelial-mesenchymal transition (EMT) process.

Authors:  Lin Lu; Zhiqiang Zha; Peiling Zhang; Dailing Li; Guolong Liu
Journal:  Int J Med Sci       Date:  2021-10-15       Impact factor: 3.738

9.  Tetraspanin CD82 drives acute myeloid leukemia chemoresistance by modulating protein kinase C alpha and β1 integrin activation.

Authors:  Muskan Floren; Sebastian Restrepo Cruz; Christina M Termini; Kristopher D Marjon; Keith A Lidke; Jennifer M Gillette
Journal:  Oncogene       Date:  2020-03-19       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.